Neocella is a biotechnology company focused on cancer treatment through the application of cancer immunology, genomics, and T-cell biology. Their AI-driven therapies utilize cell and gene technologies to enhance immune responses against tumors, aiming to improve patient outcomes and quality of life.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer treatment faces challenges in effectively targeting tumors and eliciting robust immune responses, leading to limited efficacy and potential side effects. Traditional approaches may not fully harness the body's immune system to recognize and eliminate cancer cells, resulting in disease progression and reduced patient survival rates.
Solution
Neocella is developing AI-driven cancer immunotherapies that leverage cell and gene technologies to enhance the body's natural defenses against tumors. Their approach focuses on engineering T-cells to specifically recognize and attack cancer cells, while also modulating the tumor microenvironment to promote immune cell infiltration and activity. By integrating genomics and advanced bioinformatics, Neocella aims to create personalized therapies that are tailored to the unique characteristics of each patient's cancer. The goal is to improve treatment outcomes, minimize off-target effects, and ultimately eradicate cancer while enhancing patients' quality of life.
Target Audience
The primary target audience includes cancer patients with advanced or refractory solid tumors, as well as oncologists and hematologists seeking innovative treatment options.
Features
- AI-driven identification of novel cancer-specific targets for T-cell engineering
- Proprietary cell and gene technologies to enhance T-cell activation, proliferation, and tumor infiltration
- Personalized immunotherapy approaches based on individual patient genomics and tumor profiling
- Modulation of the tumor microenvironment to overcome immune suppression